Five things for pharma marketers to know: Friday, November 4, 2016
Photo credit: StockMonkeys.com/Creative Commons
1. An antitrust investigation by the Justice Department may lead to criminal charges for a number of makers of generic drugs over price collusion. Mylan, Teva Pharmaceutical Industries, Endo International, and others have disclosed that they've received subpoenas. (Bloomberg)
2. The FDA's drug-approval team has 700 vacancies. Director for the Center for Drug Evaluation and Research Janet Woodcock said that industry lures top candidates away with higher pay. (Kaiser Health News)
3. Novo Nordisk's stranglehold in the hemophilia business is threatened by a new drug from Roche, ACE910. NovoSeven, the Danish drugmaker's $1.5 billion a year hemophilia treatment, is 20 years old. (Bloomberg)
4. The FDA's Office of Prescription Drug Promotion issued an untitled letter to Supernus Pharmaceuticals over a Spanish-language promotional video discussing seizure drug Oxtellar XR.
5. A poll conducted by the Biosimilars Forum said that less than half of U.S. physicians it polled think biosimilars will be safe and appropriate for use in existing and new patients. (Chain Drug Review)